U.S. Markets closed

Today's Research Reports on CardioComm Solutions, Nuvo Pharmaceuticals, Sernova and Microbix Biosystems

NEW YORK, NY / ACCESSWIRE / September 25, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

Sernova Corp.
https://rdinvesting.com/news/?ticker=SVA.V

Microbix Biosystems Inc.
https://rdinvesting.com/news/?ticker=MBX.TO

CardioComm Solutions’ stock had no change Monday, to close the day at $0.045. The stock recorded a trading volume of 60,272 shares, which was below its three months average volume of 117,885 shares. In the last year, CardioComm Solutions' shares have traded in a range of 0.05 - 0.08. The share price has fallen 0% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.05 is lower than its 200-day moving average of $0.052. Shares of CardioComm Solutions have fallen approximately 10 percent year-to-date.

Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V

On Monday, shares of Nuvo Pharmaceuticals recorded a trading volume of 13,615 shares, which was above the three months average volume of 10,890 shares. The stock ended the day flat at $2.71. The share price has fallen 39.64% from its 52 week high with a 52 week trading range of 2.55 - 4.49. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.89 is lower than its 200-day moving average of $2.97. Shares of the company are trading at a Price to Earnings ratio of 67.75. Shares of Nuvo Pharmaceuticals have fallen approximately 26.76 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

Sernova’s stock moved 2.38% higher Monday, to close the day at $0.215. The stock recorded a trading volume of 105,500 shares, which was below its three months average volume of 170,040 shares. In the last year, Sernova's shares have traded in a range of 0.18 - 0.51. The share price has gained 19.44% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.21 is lower than its 200-day moving average of $0.271. Shares of Sernova have fallen approximately 48.81 percent year-to-date.

Access RDI's Sernova Corp. Research Report at:
https://rdinvesting.com/news/?ticker=SVA.V

On Monday, shares of Microbix Biosystems recorded a trading volume of 29,500 shares, which was below the three months average volume of 48,779 shares. The stock ended the day 4% lower at $0.24. The share price has fallen 36.84% from its 52 week high with a 52 week trading range of 0.22 - 0.38. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.26 is lower than its 200-day moving average of $0.28. Shares of Microbix Biosystems have fallen approximately 22.58 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MBX.TO

Our Actionable Research on CardioComm Solutions, Inc. (TSXV:EKG.V), Nuvo Pharmaceuticals Inc. (TSX:NRI.TO), Sernova Corp. (TSXV:SVA.V) and Microbix Biosystems Inc. (TSX:MBX.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com